BCMA x CD3 T-cell engager in a patient with penta-refractory multiple myeloma and HIV: a clinical and immunological report
Cords L, Schaefers C, Kamili A, Hoffmann C, Cichutek S, Haag F, Polywka S, Bokemeyer C, Leypoldt L, Alsdorf W, Schulze zur Wiesch J, Weisel K
HAEMATOLOGICA. 2024;109(9):3071-3077.

SARS-CoV-2 vaccination may mitigate dysregulation of IL-1/IL-18 and gastrointestinal symptoms of the post-COVID-19 condition
Fischer C, Willscher E, Paschold L, Gottschick C, Klee B, Diexer S, Bosurgi L, Dutzmann J, Sedding D, Frese T, Girndt M, Hoell J, Gekle M, Addo M, Schulze Zur Wiesch J, Mikolajczyk R, Binder M, Schultheiß C
NPJ VACCINES. 2024;9(1):23.

Antiinfektiva-Therapie bei eingeschränkter Leberfunktion / - zirrhose
Lohse A, Schulze zur Wiesch J
2024. Infektionstherapie: Antibiotika, Virostatika, Antimykotika, Antiparasitäre Wirkstoffe. Brodt H, Hörauf A, Kresken M, Solbach W, Welte T (eds.). 13. ed. Georg Thieme Verlag, 1117-1119.

Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and liver transplant recipients
Murray S, Pose E, Wittner M, Londoño M, Schaub G, Cook J, Dimitriadis S, Meacham G, Irwin S, Lim Z, Duengelhoef P, Sterneck M, Lohse A, Perez V, Trivedi P, Bhandal K, Mullish B, Manousou P, Provine N, Avitabile E, Carroll M, Tipton T, Healy S, Burra P, Klenerman P, Dunachie S, Kronsteiner B, Maciola A, Pasqual G, Hernandez-Gea V, Garcia-Pagan J, Lampertico P, Iavarone M, Gines P, Lütgehetmann M, Schulze Zur Wiesch J, Russo F, Barnes E, Marjot T
J HEPATOL. 2024;80(1):109-123.

Lack of evidence of acute HEV infections as a sexually transmitted disease: Data from a German cohort of PrEP users
Schäfer G, Lübke R, Degen O, Mader M, Scheiter R, Wolski A, Addo M, Schulze Zur Wiesch J, Pischke S
BRAZ J INFECT DIS. 2024;28(1):103720.

High vaccination coverage and infection rate result in a robust SARS-CoV-2-specific immunity in the majority of liver cirrhosis and transplant patients: A single-center cross-sectional study
von der Schulenburg P, Herting A, Harberts A, Lütgehetmann M, Jahnke-Triankowski J, Pischke S, Piecha F, Drolz A, Jörg V, Hübener P, Wehmeyer M, Addo M, Fischer L, Lohse A, Schulze Zur Wiesch J, Sterneck M
UNITED EUR GASTROENT. 2024;12(3):339-351.

Immunosuppressive M2 TAMs represent a promising target population to enhance phagocytosis of ovarian cancer cells in vitro
Brauneck F, Schmalfeldt B, Muschhammer J, Sturmheit T, Ackermann C, Haag F, Schulze Zur Wiesch J, Ding Y, Qi M, Hell L, Schmalfeldt B, Bokemeyer C, Fiedler W, Wellbrock J
FRONT IMMUNOL. 2023;14:1250258.

Comparative analysis of characteristics and outcomes in hospitalized COVID-19 patients infected with different SARS-CoV-2 variants between January 2020 and April 2022 - A retrospective single-center cohort study
Brehm T, Heyer A, Woo M, Fischer M, van der Meirschen M, Wichmann D, Jarczak D, Roedl K, Schmiedel S, Addo M, Lütgehetmann M, Christner M, Huber S, Lohse A, Kluge S, Schulze Zur Wiesch J
J INFECT PUBLIC HEAL. 2023;16(11):1806-1812.

Frequency of IRF5+ dendritic cells is associated with the TLR7-induced inflammatory cytokine response in SARS-CoV-2 infection
Cords L, Woost R, Kummer S, Brehm T, Kluge S, Schmiedel S, Jordan S, Lohse A, Altfeld M, Addo M, Schulze Zur Wiesch J, Beisel C
CYTOKINE. 2023;162:.

Treating hepatitis D with bulevirtide - Real-world experience from 114 patients
Dietz-Fricke C, Tacke F, Zöllner C, Demir M, Schmidt H, Schramm C, Willuweit K, Lange C, Weber S, Denk G, Berg C, Grottenthaler J, Merle U, Olkus A, Zeuzem S, Sprinzl K, Berg T, van Bömmel F, Wiegand J, Herta T, Seufferlein T, Zizer E, Dikopoulos N, Thimme R, Neumann-Haefelin C, Galle P, Sprinzl M, Lohse A, Schulze Zur Wiesch J, Kempski J, Geier A, Reiter F, Schlevogt B, Gödiker J, Hofmann W, Buggisch P, Kahlhöfer J, Port K, Maasoumy B, Cornberg M, Wedemeyer H, Deterding K
JHEP REP. 2023;5(4):100686.

Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure
Dietz J, Müllhaupt B, Buggisch P, Graf C, Peiffer K, Matschenz K, Schattenberg J, Antoni C, Mauss S, Niederau C, Discher T, Trauth J, Dultz G, Schulze Zur Wiesch J, Piecha F, Klinker H, Müller T, Berg T, Neumann-Haefelin C, Berg C, Zeuzem S, Sarrazin C
J HEPATOL. 2023;78(1):57-66.

Emergence of resistance-associated variants during sofosbuvir treatment in chronically infected hepatitis E patients
Gömer A, Klöhn M, Jagst M, Nocke M, Pischke S, Horvatits T, Schulze Zur Wiesch J, Müller T, Hardtke S, Cornberg M, Wedemeyer H, Behrendt P, Steinmann E, Todt D
HEPATOLOGY. 2023;78(6):1882-1895.

Analysis of the humoral and cellular response after the third COVID-19 vaccination in patients with autoimmune hepatitis
Hartl J, Rüther D, Duengelhoef P, Brehm T, Steinmann S, Weltzsch J, Glaser F, Sterneck M, Sebode M, Weiler-Normann C, Lütgehetmann M, Schaub G, Haag F, Schramm C, Schulze Zur Wiesch J, Lohse A
LIVER INT. 2023;43(2):393-400.

Tecovirimat for the treatment of severe Mpox in Germany
Hermanussen L, Brehm T, Wolf T, Boesecke C, Schlabe S, Borgans F, Monin M, Jensen B, Windhaber S, Scholten S, Jordan S, Lütgehetmann M, Wiesch J, Addo M, Mikolajewska A, Niebank M, Schmiedel S
INFECTION. 2023;51(5):1563-1568.

Tecovirimat therapy for severe monkeypox infection: Longitudinal assessment of viral titers and clinical response pattern-A first case-series experience
Hermanussen L, Grewe I, Tang H, Nörz D, Bal L, Pfefferle S, Unger S, Hoffmann C, Berzow D, Kohsar M, Aepfelbacher M, Lohse A, Addo M, Lütgehetmann M, Schulze zur Wiesch J, Schmiedel S
J MED VIROL. 2023;95(1):e28181.

Non-organ-specific autoantibodies with unspecific patterns are a frequent para-infectious feature of chronic hepatitis D
Hermanussen L, Lampalzer S, Bockmann J, Ziegler A, Piecha F, Dandri M, Pischke S, Haag F, Lohse A, Lütgehetmann M, Weiler-Normann C, Zur Wiesch J
FRONT MED-LAUSANNE. 2023;10:1169096.

Clinical Outcomes of SARS-CoV-2 Breakthrough Infections in Liver Transplant Recipients during the Omicron Wave
Herting A, Jahnke-Triankowski J, Harberts A, Schaub G, Lütgehetmann M, Ruether D, Fischer L, Addo M, Lohse A, Schulze Zur Wiesch J, Sterneck M
VIRUSES-BASEL. 2023;15(2):.

Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study
Lemoine M, Assoumou L, Girard P, Valantin M, Katlama C, De Wit S, Campa P, Rougier H, Meynard J, Necsoi C, Huefner A, Van Luzen J, Schulze Zur Wiesch J, Bastard J, Fellahi S, Mauss S, Stankov M, Baumgarten A, Post G, Serfaty L, Ratziu V, Menu Y, Schlue J, Bedossa P, Capeau J, Costagliola D, Behrens G, Ingiliz P
CLIN GASTROENTEROL H. 2023;21(3):713-722.e3.

TREM2 Regulates the Removal of Apoptotic Cells and Inflammatory Processes during the Progression of NAFLD
Liebold I, Meyer S, Heine M, Kuhl A, Witt J, Eissing L, Fischer A, Koop A, Kluwe J, Wiesch J, Wehmeyer M, Knippschild U, Scheja L, Heeren J, Bosurgi L, Worthmann A
CELLS-BASEL. 2023;12(3):.

Treatment and Concomitant Infections in Refugees From the Ukraine With HIV
Matthews H, In A, Völker K, Hertling S, Hoffmann C, Schäfer G, Unger S, Schulze Zur Wiesch J, AD H, Jordan S, Degen O, Schmiedel S
DTSCH ARZTEBL INT. 2023;120(31-32):540-541.

History of cerebrovascular disease but not dementia increases the risk for secondary vascular events during SARS-CoV-2 infection with presumed Omicron variant: a retrospective observational study
Mayer C, Woo M, Brehm T, Heyer A, Fischer M, Fischbach F, Bal L, Addo M, Kluge S, Thomalla G, Schweingruber N, Wiesch J
EUR J NEUROL. 2023;30(8):2297-2304.

High incidence of periodontitis in patients with ascitic decompensated cirrhosis
Pischke S, Ashouri M, Peters U, Shiprov A, Schulze Zur Wiesch J, Sterneck M, Fischer F, Huebener P, Mader M, Fischer L, Fründt T, Aarabi G, Beikler T
WORLD J HEPATOL. 2023;15(12):1325-1332.

Anti-HEV seroprevalence and rate of viremia in a German cohort of dogs, cats, and horses
Pischke S, Knoop E, Mader M, Kling L, Wolski A, Wagner A, Mueller K, Horvatits T, Stiller J, Wisnewski K, Kohn B, Schulze Zur Wiesch J, Groschup M, Eiden M
SCI REP-UK. 2023;13(1):19240.

High prevalence of periodontal disease in patients with NASH- possible association of poor dental health with NASH severity
Pischke S, Shiprov A, Peters U, Schulze Zur Wiesch J, Kluwe J, Westphal T, Fischer F, Mader M, Fründt T, Horvatits K, Horvatits T, Aarabi G, Beikler T
ANN HEPATOL. 2023;28(2):.

Longitudinal SARS-CoV-2 Seroprevalence among Employees in Outpatient Care Services in Hamburg
Schablon A, Harth V, Terschüren C, Kleinmüller O, Wohlert C, Schnabel C, Brehm T, Schulze zur Wiesch J, Kersten J, Nienhaus A
INT J ENV RES PUB HE. 2023;20(8):.

Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial
Wedemeyer H, Schöneweis K, Bogomolov P, Blank A, Voronkova N, Stepanova T, Sagalova O, Chulanov V, Osipenko M, Morozov V, Geyvandova N, Sleptsova S, Bakulin I, Khaertynova I, Rusanova M, Pathil A, Merle U, Bremer B, Allweiss L, Lempp F, Port K, Haag M, Schwab M, Zur Wiesch J, Cornberg M, Haefeli W, Dandri M, Alexandrov A, Urban S
LANCET INFECT DIS. 2023;23(1):117-129.

Prospective Single-Center Cohort Study on HIV Pre-exposure Prophylaxis Reveals Transient but Relevant Elevations in Transaminase Levels in Some Participants Albeit Otherwise High Tolerability
Weimann L, Schäfer G, Matthews H, Florey M, Scheiter R, Hüfner A, Jordan S, Grenz M, Schmiedel S, Schulze Zur Wiesch J, Degen O, Koch T
JAIDS-J ACQ IMM DEF. 2023;93(1):e1-e3.

Evidence for broad cross-reactivity of the SARS-CoV-2 NSP12-directed CD4+ T-cell response with pre-primed responses directed against common cold coronaviruses
Westphal T, Mader M, Karsten H, Cords L, Knapp M, Schulte S, Hermanussen L, Peine S, Ditt V, Grifoni A, Addo M, Huber S, Sette A, Lütgehetmann M, Pischke S, Kwok W, Sidney J, Schulze Zur Wiesch J
FRONT IMMUNOL. 2023;14:.

Sotrovimab in Hospitalized Patients with SARS-CoV-2 Omicron Variant Infection: a Propensity Score-Matched Retrospective Cohort Study
Woo M, Brehm T, Fischer M, Heyer A, Wichmann D, Jordan S, Nörz D, Lütgehetmann M, Addo M, Lohse A, Schmiedel S, Kluge S, Schulze Zur Wiesch J
MICROBIOL SPECTR. 2023;11(1):.

Absence of self-reported neuropsychiatric and somatic symptoms after Omicron variant SARS-CoV-2 breakthrough infections
Woo M, Mayer C, Brehm T, Andersen G, Weigel A, Löwe B, Lohse A, Addo M, Gerloff C, Knobloch J, Schulze Zur Wiesch J, Friese M
BRAIN COMMUN. 2023;5(2):fcad092.

Clinical surrogates of dysautonomia predict lethal outcome in COVID-19 on intensive care unit
Woo M, Mayer C, Fischer M, Kluge S, Roedl K, Gerloff C, Czorlich P, Thomalla G, Schulze Zur Wiesch J, Schweingruber N
NEUROL RES PRACT. 2023;5(1):17.

Vagus nerve inflammation contributes to dysautonomia in COVID-19
Woo M, Shafiq M, Fitzek A, Dottermusch M, Altmeppen H, Mohammadi B, Mayer C, Bal L, Raich L, Matschke J, Krasemann S, Pfefferle S, Brehm T, Lütgehetmann M, Schädler J, Addo M, Schulze Zur Wiesch J, Ondruschka B, Friese M, Glatzel M
ACTA NEUROPATHOL. 2023;146(3):387-394.

Human dental pulp cells modulate CD8+ T cell proliferation and efficiently degrade extracellular ATP to adenosine in vitro
Ahmadi P, Yan M, Bauche A, Smeets R, Müller C, Koch-Nolte F, Haag F, Fliegert R, Kluwe L, Schulze Zur Wiesch J, Hartjen P
CELL IMMUNOL. 2022;380:.

T cells expressing multiple co-inhibitory molecules in acute malaria are not exhausted but exert a suppressive function in mice
Brandi J, Lehmann C, Kaminski L, Schulze Zur Wiesch J, Addo M, Ramharter M, Mackroth M, Jacobs T, Riehn M
EUR J IMMUNOL. 2022;52(2):312-327.

Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants
Brehm T, Pfefferle S, von Possel R, Karolyi M, Zoufaly A, Wichmann D, Kobbe R, Emmerich P, Nörz D, Aepfelbacher M, Schulze Zur Wiesch J, Addo M, Schmiedel S, Lütgehetmann M
J MED VIROL. 2022;94(10):5038-5043.

Three Separate Spike Antigen Exposures by COVID-19 Vaccination or SARS-CoV-2 Infection Elicit Strong Humoral Immune Responses in Healthcare Workers
Brehm T, Ullrich F, Thompson M, Küchen J, Schwinge D, Spier A, Huber S, Knobloch J, Aepfelbacher M, Addo M, Lohse A, Lütgehetmann M, Schulze Zur Wiesch J
VACCINES-BASEL. 2022;10(7):.

High and Sustained Ex Vivo Frequency but Altered Phenotype of SARS-CoV-2-Specific CD4+ T-Cells in an Anti-CD20-Treated Patient with Prolonged COVID-19
Cords L, Knapp M, Woost R, Schulte S, Kummer S, Ackermann C, Beisel C, Peine S, Johansson A, Kwok W, Günther T, Fischer N, Wittner M, Addo M, Huber S, Schulze Zur Wiesch J
VIRUSES-BASEL. 2022;14(6):.

SARS-CoV-2 vaccination response in patients with autoimmune hepatitis and autoimmune cholestatic liver disease
Duengelhoef P, Hartl J, Rüther D, Steinmann S, Brehm T, Weltzsch J, Glaser F, Schaub G, Sterneck M, Sebode M, Weiler-Normann C, Addo M, Lütgehetmann M, Haag F, Schramm C, Schulze Zur Wiesch J, Lohse A
UNITED EUR GASTROENT. 2022;10(3):319-329.

Risk factors for worsening of somatic symptom burden in a prospective cohort during the COVID-19 pandemic
Engelmann P, Löwe B, Brehm T, Weigel A, Ullrich F, Addo M, Schulze zur Wiesch J, Lohse A, Toussaint A
FRONT PSYCHOL. 2022;13:1022203.

Clinical features of hepatitis E infections in patients with hematologic disorders
Ghandili S, Lindhauer C, Pischke S, Zur Wiesch J, Von Kroge P, Polywka S, Bokemeyer C, Fiedler W, Kröger N, Ayuk F, Adjallé R, Modemann F
HAEMATOLOGICA. 2022;107(12):2870-2883.

Natural killer cell-mediated ADCC in SARS-CoV-2-infected individuals and vaccine recipients
Hagemann K, Riecken K, Jung J, Hildebrandt H, Menzel S, Bunders M, Fehse B, Koch-Nolte F, Heinrich F, Peine S, Schulze Zur Wiesch J, Brehm T, Addo M, Lütgehetmann M, Altfeld M
EUR J IMMUNOL. 2022;52(8):1297-1307.

Humoral and Cellular Immune Response After Third and Fourth SARS-CoV-2 mRNA Vaccination in Liver Transplant Recipients
Harberts A, Schaub G, Ruether D, Duengelhoef P, Brehm T, Karsten H, Fathi A, Jahnke-Triankowski J, Fischer L, Addo M, Haag F, Lütgehetmann M, Lohse A, Schulze zur Wiesch J, Sterneck M
CLIN GASTROENTEROL H. 2022;20(11):2558-2566.e5.

Correction: Broadly directed SARS-CoV-2-specific CD4+ T cell response includes frequently detected peptide specificities within the membrane and nucleoprotein in patients with acute and resolved COVID-19
Heide J, Schulte S, Kohsar M, Brehm T, Herrmann M, Karsten H, Marget M, Peine S, Johansson A, Sette A, Lütgehetmann M, Kwok W, Sidney J, Schulze Zur Wiesch J
PLOS PATHOG. 2022;18(1):.

Respiratory muscle dysfunction in long-COVID patients
Hennigs J, Huwe M, Hennigs A, Oqueka T, Simon M, Harbaum L, Körbelin J, Schmiedel S, Schulze Zur Wiesch J, Addo M, Kluge S, Klose H
INFECTION. 2022;50(5):1391-1397.

Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection
Heyer A, Günther T, Robitaille A, Lütgehetmann M, Addo M, Jarczak D, Kluge S, Aepfelbacher M, Schulze Zur Wiesch J, Fischer N, Grundhoff A
CELL REP MED. 2022;3(9):.

Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals
Howe A, Rodrigo C, Cunningham E, Douglas M, Dietz J, Grebely J, Popping S, Sfalcin J, Parczewski M, Sarrazin C, de Salazar A, Fuentes A, Sayan M, Quer J, Kjellin M, Kileng H, Mor O, Lennerstrand J, Fourati S, Di Maio V, Chulanov V, Pawlotsky J, Harrigan P, Ceccherini-Silberstein F, Garcia F
JHEP REP. 2022;4(5):.

Autopsy Study Defines Composition and Dynamics of the HIV-1 Reservoir after Allogeneic Hematopoietic Stem Cell Transplantation with CCR5Δ32/Δ32 Donor Cells
Huyveneers L, Bruns A, Stam A, Ellerbroek P, de Jong D, Nagy N, Gumbs S, Tesselaar K, Bosman K, Salgado M, Hütter G, Brosens L, Kwon M, Diez Martin J, van der Meer J, de Kort T, Sáez-Cirión A, Schulze Zur Wiesch J, Boelens J, Martinez-Picado J, Kuball J, Wensing A, Nijhuis M
VIRUSES-BASEL. 2022;14(9):.

High-resolution analysis of individual spike peptide-specific CD4+ T-cell responses in vaccine recipients and COVID-19 patients
Karsten H, Cords L, Westphal T, Knapp M, Brehm T, Hermanussen L, Omansen T, Schmiedel S, Woost R, Ditt V, Peine S, Lütgehetmann M, Huber S, Ackermann C, Wittner M, Addo M, Sette A, Sidney J, Schulze Zur Wiesch J
CLIN TRANSL IMMUNOL. 2022;11(8):.

Inversed Ratio of CD39/CD73 Expression on γδ T Cells in HIV Versus Healthy Controls Correlates With Immune Activation and Disease Progression
Kolbe K, Wittner M, Hartjen P, Hüfner A, Degen O, Ackermann C, Cords L, Stellbrink H, Haag F, Schulze Zur Wiesch J
FRONT IMMUNOL. 2022;13:.

Efficacy of Tigecycline as Salvage Therapy in Multidrug-Resistant Febrile Neutropenia in Patients with Acute Leukemia-A Single Center Analysis
Modemann F, Härterich S, Schulze Zur Wiesch J, Rohde H, Lindeman N, Bokemeyer C, Fiedler W, Ghandili S
ANTIBIOTICS-BASEL. 2022;11(2):.

Clinical characteristics and comparison of longitudinal qPCR results from different specimen types in a cohort of ambulatory and hospitalized patients infected with monkeypox virus
Nörz D, Brehm T, Tang H, Grewe I, Hermanussen L, Matthews H, Pestel J, Degen O, Günther T, Grundhoff A, Fischer N, Addo M, Jordan S, Hertling S, Unger S, Schäfer G, Schewe K, Hoffmann C, Aepfelbacher M, Pfefferle S, Schulze Zur Wiesch J, Schmiedel S, Lütgehetmann M
J CLIN VIROL. 2022;155:.

Evidence of surface contamination in hospital rooms occupied by patients infected with monkeypox, Germany, June 2022
Nörz D, Pfefferle S, Brehm T, Franke G, Grewe I, Knobling B, Aepfelbacher M, Huber S, Klupp E, Jordan S, Addo M, Schulze Zur Wiesch J, Schmiedel S, Lütgehetmann M, Knobloch J
EUROSURVEILLANCE. 2022;27(26):.

Specific CD4+ T Cell Responses to Ancestral SARS-CoV-2 in Children Increase With Age and Show Cross-Reactivity to Beta Variant
Paul K, Sibbertsen F, Weiskopf D, Lütgehetmann M, Barroso M, Danecka M, Glau L, Hecher L, Hermann K, Kohl A, Oh J, Wiesch J, Sette A, Tolosa E, Vettorazzi E, Woidy M, Zapf A, Zazara D, Mir T, Muntau A, Gersting S, Dunay G
FRONT IMMUNOL. 2022;13:867577.

SARS-CoV2-specific humoral and T-cell immune response after second vaccination in liver cirrhosis and transplant patients
Ruether D, Schaub G, Duengelhoef P, Haag F, Brehm T, Fathi A, Wehmeyer M, Jahnke-Triankowski J, Mayer L, Hoffmann A, Fischer L, Addo M, Lütgehetmann M, Lohse A, Schulze Zur Wiesch J, Sterneck M
CLIN GASTROENTEROL H. 2022;20(1):162-172.e9.

Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients-COVIDOUT study
Schönlein M, Wrage V, Ghandili S, Mellinghoff S, Brehm T, Leypoldt L, Utz N, Schrader R, Alsdorf W, Börschel N, Bußmann L, Schönrock M, Perlick D, Schön G, Verpoort K, Lütgehetmann M, Schulze Zur Wiesch J, Weisel K, Bokemeyer C, Schafhausen P, Sinn M
CANCER CELL. 2022;40(6):581-583.

Deciphering the Plasmodium falciparum malaria-specific CD4+ T-cell response: ex vivo detection of high frequencies of PD-1+TIGIT+ EXP1-specific CD4+ T cells using a novel HLA-DR11-restricted MHC class II tetramer
Schulte S, Heide J, Ackermann C, Peine S, Ramharter M, Mackroth M, Woost R, Jacobs T, Schulze Zur Wiesch J
CLIN EXP IMMUNOL. 2022;207(2):227-236.

Factors associated with severity and persistence of fatigue in patients with primary biliary cholangitis: study protocol of a prospective cohort study with a mixed-methods approach (SOMA.LIV)
Toussaint A, Buck L, Hartl J, Löwe B, Schramm C
BMJ OPEN. 2022;12(12):.

Erratum zu: Milde COVID-19-Verläufe bei Mitarbeitenden einer Universitätsklinik : Die „erste Welle“ am Universitätsklinikum Hamburg-Eppendorf
von Felden J, Brehm T, Schulze Zur Wiesch J, Addo M, Lohse A, Knobloch J, Koch T
BUNDESGESUNDHEITSBLA. 2022;65(3):398.

Immune escape pathways from the HBV core18-27 CD8 T cell response are driven by individual HLA class I alleles
Walker A, Schwarz T, Brinkmann-Paulukat J, Wisskirchen K, Menne C, Alizei E, Kefalakes H, Theissen M, Hoffmann D, Schulze Zur Wiesch J, Maini M, Cornberg M, Kraft A, Keitel V, Bock H, Horn P, Thimme R, Wedemeyer H, Heinemann F, Luedde T, Neumann-Haefelin C, Protzer U, Timm J
FRONT IMMUNOL. 2022;13:.

Frequent detection of functional hyposplenism via assessment of pitted erythrocytes in patients with advanced liver cirrhosis
Wehmeyer M, Sekhri H, Wroblewski R, Galante A, Meyer T, Lohse A, Schulze Zur Wiesch J
PLOS ONE. 2022;17(7):.

Einstellungen gegenüber der COVID-19-Impfung im Vergleich zur Grippeschutzimpfung bei Krankenhauspersonal
Weigel A, Brehm T, Schulze zur Wiesch J, Vogt B, Lohse A, Löwe B
PSYCHOTHER PSYCH MED. 2022;72(8):382-385.

Lack of Evidence of Hepatitis E Virus Infections in a Cohort of Boars and Deer Species in a Game Reserve in Northern Germany
Westphal T, Delling M, Mader M, Ackermann C, Horvatits T, Lütgehetmann M, Schulze zur Wiesch J, Pischke S, Beisel C
Zoonotic Diseases. 2022;2(4):228-233.

Transcriptional Pattern Analysis of Virus-Specific CD8+ T Cells in Hepatitis C Infection: Increased Expression of TOX and Eomesodermin During and After Persistent Antigen Recognition
Wildner N, Walker A, Brauneck F, Ditt V, Peine S, Huber S, Haag F, Beisel C, Timm J, Schulze Zur Wiesch J
FRONT IMMUNOL. 2022;13:.

Real-world Effectiveness of Glecaprevir/Pibrentasvir (GLE/PIB) for Chronic Hepatitis C Infection: Evidence From a German Single-center Cohort Study
Beisel C, Herrmann M, Piecha F, Lampalzer S, Buescher G, Pischke S, Schulze zur Wiesch J
HEPAT MON. 2021;21(1):e110077.

High Rates of Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic and Cardiovascular Comorbidities
Bockmann J, Kohsar M, Murray J, Hamed V, Dandri-Petersen M, Lüth S, Lohse A, Schulze-Zur-Wiesch J
MICROORGANISMS. 2021;9(5):.

Increased frequency of TIGIT+CD73-CD8+ T cells with a TOX+ TCF-1low profile in patients with newly diagnosed and relapsed AML
Brauneck F, Haag F, Woost R, Wildner N, Tolosa E, Rissiek A, Vohwinkel G, Wellbrock J, Bokemeyer C, Schulze Zur Wiesch J, Ackermann C, Fiedler W
ONCOIMMUNOLOGY. 2021;10(1):1930391.

Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML
Brauneck F, Seubert E, Wellbrock J, Schulze Zur Wiesch J, Duan Y, Magnus T, Bokemeyer C, Koch-Nolte F, Menzel S, Fiedler W
INT J MOL SCI. 2021;22(23):.

Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma
Brauneck F, Weimer P, Schulze zur Wiesch J, Weisel K, Leypoldt L, Vohwinkel G, Fritzsche B, Bokemeyer C, Wellbrock J, Fiedler W
FRONT MED-LAUSANNE. 2021;8:763773.

Patient Characteristics and Clinical Course of COVID-19 Patients Treated at a German Tertiary Center during the First and Second Waves in the Year 2020
Brehm T, Heyer A, Roedl K, Jarczak D, Nierhaus A, Nentwich M, van der Meirschen M, Schultze A, Christner M, Fiedler W, Kröger N, Huber T, Klose H, Sterneck M, Jordan S, Kreuels B, Schmiedel S, Addo M, Huber S, Lohse A, Kluge S, Schulze Zur Wiesch J
J CLIN MED. 2021;10(11):.

Lower Levels of Transaminases but Higher Levels of Serum Creatinine in Patients with Acute Hepatitis E in Comparison to Patients with Hepatitis A
Brehm T, Mazaheri O, Horvatits T, Lütgehetmann M, Schulze Zur Wiesch J, Lohse A, Polywka S, Pischke S
PATHOGENS. 2021;10(1):60.

SARS-CoV-2 Reinfection in a Healthcare Worker Despite the Presence of Detectable Neutralizing Antibodies
Brehm T, Pfefferle S, von Possel R, Kobbe R, Nörz D, Schmiedel S, Grundhoff A, Olearo F, Emmerich P, Robitaille A, Günther T, Braun P, Andersen G, Knobloch J, Addo M, Lohse A, Aepfelbacher M, Fischer N, Schulze Zur Wiesch J, Lütgehetmann M
VIRUSES-BASEL. 2021;13(4):.

Seroprevalence of SARS-CoV-2 antibodies among hospital workers in a German tertiary care center: A sequential follow-up study
Brehm T, Schwinge D, Lampalzer S, Schlicker V, Küchen J, Thompson M, Ullrich F, Huber S, Schmiedel S, Addo M, Lütgehetmann M, Knobloch J, Schulze Zur Wiesch J, Lohse A
INT J HYG ENVIR HEAL. 2021;232:.

Low SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic
Brehm T, Thompson M, Ullrich F, Schwinge D, Addo M, Spier A, Knobloch J, Aepfelbacher M, Lohse A, Lütgehetmann M, Schulze Zur Wiesch J
INT J HYG ENVIR HEAL. 2021;238:.

Comparison of clinical characteristics and disease outcome of COVID-19 and seasonal influenza
Brehm T, van der Meirschen M, Hennigs A, Roedl K, Jarczak D, Wichmann D, Frings D, Nierhaus A, Oqueka T, Fiedler W, Christopeit M, Kraef C, Schultze A, Lütgehetmann M, Addo M, Schmiedel S, Kluge S, Schulze Zur Wiesch J
SCI REP-UK. 2021;11(1):.

S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11)
Cornberg M, Sandmann L, Protzer U, Niederau C, Tacke F, Berg T, Glebe D, Jilg W, Wedemeyer H, Wirth S, Höner Zu Siederdissen C, Lynen-Jansen P, van Leeuwen P, Petersen J
Z GASTROENTEROL. 2021;59(7):691-776.

Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy
Dietz J, Di Maio V, de Salazar A, Merino D, Vermehren J, Paolucci S, Kremer A, Lara M, Pardo M, Zoller H, Degasperi E, Peiffer K, Sighinolfi L, Téllez F, Graf C, Ghisetti V, Schreiber J, Fernández-Fuertes E, Boglione L, Muñoz-Medina L, Stauber R, Gennari W, Figueruela B, Santos J, Lampertico P, Zeuzem S, Ceccherini-Silberstein F, García F, Sarrazin C
J HEPATOL. 2021;74(4):801-810.

Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections
Dietz J, Spengler U, Müllhaupt B, Schulze Zur Wiesch J, Piecha F, Mauss S, Seegers B, Hinrichsen H, Antoni C, Wietzke-Braun P, Peiffer K, Berger A, Matschenz K, Buggisch P, Backhus J, Zizer E, Boettler T, Neumann-Haefelin C, Semela D, Stauber R, Berg T, Berg C, Zeuzem S, Vermehren J, Sarrazin C
CLIN GASTROENTEROL H. 2021;19(1):195-198.e2.

Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity
Drolz A, Wolter S, Wehmeyer M, Piecha F, Horvatits T, Schulze Zur Wiesch J, Lohse A, Mann O, Kluwe J
INT J OBESITY. 2021;45(10):2197-2204.

Low incidence of COVID-19 in a prospective cohort of patients with liver cirrhosis and hepatocellular carcinoma treated at a tertiary medical center during the 2020 pandemic
Fründt T, Kuballa L, Lütgehetman M, Nörz D, Arend H, Brehm T, Schulze Zur Wiesch J, Horvatits T, Horvatits K, Huber S, Wege H, Kluwe J
PLOS ONE. 2021;16(12):e0258450.

Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment
Ghandili S, Schönlein M, Lütgehetmann M, Wiesch J, Becher H, Bokemeyer C, Sinn M, Weisel K, Leypoldt L
CANCERS. 2021;13(15):.

Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma
Ghandili S, Schönlein M, Wiessner C, Becher H, Lütgehetmann M, Brehm T, Wiesch J, Bokemeyer C, Sinn M, Weisel K, Leypoldt L
J CLIN MED. 2021;10(23):.

Clinical presentation and disease course of 37 consecutive cases of progressive multifocal leukoencephalopathy (PML) at a German tertiary-care hospital: a retrospective observational study
Graf L, Rosenkranz S, Hölzemer A, Hagel C, Goebell E, Jordan S, Friese M, Addo M, Schulze zur Wiesch J, Beisel C
FRONT NEUROL. 2021;12:632535.

Broadly directed SARS-CoV-2-specific CD4+ T cell response includes frequently detected peptide specificities within the membrane and nucleoprotein in patients with acute and resolved COVID-19
Heide J, Schulte S, Kohsar M, Brehm T, Herrmann M, Karsten H, Marget M, Peine S, Johansson A, Sette A, Lütgehetmann M, Kwok W, Sidney J, Schulze Zur Wiesch J
PLOS PATHOG. 2021;17(9):.

Hepatitis E virus persists in the ejaculate of chronically infected men
Horvatits T, Wißmann J, Johne R, Groschup M, Gadicherla A, Wiesch J, Eiden M, Todt D, Reimer R, Dähnert L, Schöbel A, Horvatits K, Lübke R, Wolschke C, Ayuk F, Rybczynski M, Lohse A, Addo M, Herker E, Lütgehetmann M, Steinmann E, Pischke S
J HEPATOL. 2021;75(1):55-63.

Malaria in the Time of COVID-19: Do Not Miss the Real Cause of Illness
Jochum J, Kreuels B, Tannich E, Huber S, Schulze Zur Wiesch J, Schmiedel S, Ramharter M, Addo M
TROP MED INFECT DIS. 2021;6(2):.

Human hepatitis D virus-specific T cell epitopes
Kohsar M, Landahl J, Neumann-Haefelin C, Schulze Zur Wiesch J
JHEP REP. 2021;3(4):100294.

Handling and accuracy of four rapid antigen tests for the diagnosis of SARS-CoV-2 compared to RT-qPCR
Olearo F, Nörz D, Heinrich F, Sutter J, Roedl K, Schultze A, Wiesch J, Braun P, Oestereich L, Kreuels B, Wichmann D, Aepfelbacher M, Pfefferle S, Lütgehetmann M
J CLIN VIROL. 2021;137:.

Clinical establishment of a laboratory developed quantitative HDV PCR assay on the cobas6800 high-throughput system
Pflüger L, Nörz D, Volz T, Giersch K, Giese A, Goldmann N, Glebe D, Bockmann J, Pfefferle S, Dandri M, Schulze Zur Wiesch J, Lütgehetmann M
JHEP REP. 2021;3(6):.

Hepatitis delta virus propagation enabled by hepatitis C virus - scientifically intriguing; but is it relevant to clinical practice?
Pflüger L, Schulze Zur Wiesch J, Polywka S, Lütgehetmann M
J VIRAL HEPATITIS. 2021;28(1):213-216.

Evolution of liver stiffness and post-treatment surveillance by liver elastography for HCV patients in the DAA era
Piecha F, Gänßler J, Ozga A, Wehmeyer M, Kluwe J, Lampalzer S, Creutzfeldt A, Buescher G, Horvatits T, Sterneck M, Pischke S, Lohse A, Schulze Zur Wiesch J
SCAND J GASTROENTERO. 2021;56(7):840-848.

Lack of Evidence for an Association between Previous HEV Genotype-3 Exposure and Glomerulonephritis in General
Pischke S, Tamanaei S, Mader M, Wiesch J, Petersen-Benz C, Haddad M, Addo M, Schmidt T, Huber T, Krebs C, Steinmetz O, Turner J, Hoxha E, Horvatits T
PATHOGENS. 2021;11(1):.

Next-generation immunosequencing reveals pathological T cell architecture in autoimmune hepatitis
Schultheiß C, Germany D, Willscher E, Oberle A, Fanchi L, Bonzanni N, Wildner N, Schulze-Zur-Wiesch J, Weiler-Normann C, Lohse A, Binder M
HEPATOLOGY. 2021;73(4):1436-1448.

Landscape of T-cell repertoires with public COVID-19-associated T-cell receptors in pre-pandemic risk cohorts
Simnica D, Schultheiß C, Mohme M, Paschold L, Willscher E, Fitzek A, Püschel K, Matschke J, Ciesek S, Sedding D, Zhao Y, Gagliani N, Maringer Y, Walz J, Heide J, Schulze-Zur-Wiesch J, Binder M
CLIN TRANSL IMMUNOL. 2021;10(9):e1340.

Pro-cachectic factors link experimental and human chronic kidney disease to skeletal muscle wasting programs
Solagna F, Tezze C, Lindenmeyer M, Lu S, Wu G, Liu S, Zhao Y, Mitchell R, Meyer C, Omairi S, Kilic T, Paolini A, Ritvos O, Pasternack A, Matsakas A, Kylies D, Wiesch J, Turner J, Wanner N, Nair V, Eichinger F, Menon R, Martin I, Klinkhammer B, Hoxha E, Cohen C, Tharaux P, Boor P, Ostendorf T, Kretzler M, Sandri M, Kretz O, Puelles V, Patel K, Huber T
J CLIN INVEST. 2021;131(11):.

Psittacosis in a traveller
Veletzky L, Huebl L, Schulze Zur Wiesch J, Schmiedel S
J TRAVEL MED. 2021;28(6):.

Milde COVID-19-Verläufe bei Mitarbeitenden einer Universitätsklinik: Die „erste Welle“ am Universitätsklinikum Hamburg-Eppendorf
von Felden J, Brehm T, Schulze-Zur-Wiesch J, Addo M, Lohse A, Knobloch J, Koch T
BUNDESGESUNDHEITSBLA. 2021;64(9):1165-1168.

Editorial: only steps away from prime time? Hepatitis B virus RNA as routine marker to guide HBV treatment decisions
Wehmeyer M, Schulze zur Wiesch J
ALIMENT PHARM THER. 2021;54(7):970-971.

B cell analysis in SARS‐CoV‐2 versus malaria: Increased frequencies of plasmablasts and atypical memory B cells in COVID‐19
Wildner N, Ahmadi P, Schulte S, Brauneck F, Kohsar M, Lütgehetmann M, Beisel C, Addo M, Haag F, Schulze zur Wiesch J
J LEUKOCYTE BIOL. 2021;109(1):77-90.

Multi-dimensional and longitudinal systems profiling reveals predictive pattern of severe COVID-19
Woo M, Haag F, Nierhaus A, Jarczak D, Roedl K, Mayer C, Brehm T, van der Meirschen M, Hennigs A, Christopeit M, Fiedler W, Karagiannis P, Burdelski C, Schultze A, Huber S, Addo M, Schmiedel S, Friese M, Kluge S, Schulze Zur Wiesch J
ISCIENCE. 2021;24(7):102752.

Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients
Woo M, Steins D, Häußler V, Kohsar M, Haag F, Elias-Hamp B, Heesen C, Lütgehetmann M, Schulze Zur Wiesch J, Friese M
J NEUROL. 2021;268(1):5-7.

Clonal expansion and activation of tissue-resident memory-like Th17 cells expressing GM-CSF in the lungs of severe COVID-19 patients
Zhao Y, Kilian C, Turner J, Bosurgi L, Roedl K, Bartsch P, Gnirck A, Cortesi F, Schultheiß C, Hellmig M, Enk L, Hausmann F, Borchers A, Wong M, Paust H, Siracusa F, Scheibel N, Herrmann M, Rosati E, Bacher P, Kylies D, Jarczak D, Lütgehetmann M, Pfefferle S, Steurer S, Zur Wiesch J, Puelles V, Sperhake J, Addo M, Lohse A, Binder M, Huber S, Huber T, Kluge S, Bonn S, Panzer U, Gagliani N, Krebs C
SCI IMMUNOL. 2021;6(56):.

Defining the CD39/CD73 Axis in SARS-CoV-2 Infection: The CD73- Phenotype Identifies Polyfunctional Cytotoxic Lymphocytes
Ahmadi P, Hartjen P, Kohsar M, Kummer S, Schmiedel S, Bockmann J, Fathi A, Huber S, Haag F, Schulze Zur Wiesch J
CELLS-BASEL. 2020;9(8):.

Seroconversion of HBsAG coincides with hepatitis A super-infection: A case report
Beisel C, Addo M, Zur Wiesch J
WORLD J CLIN CASES. 2020;8(9):1651-1655.

Has Increased Rollout of Direct Acting Antiviral Therapy Decreased the Burden of Late Presentation and Advanced Liver Disease in Patients Starting Hepatitis C Virus Therapy in Germany?
Bischoff J, Boesecke C, Ingiliz P, Berger F, Simon K, Lutz T, Schewe C, Schulze Zur Wiesch J, Hueppe D, Christensen S, Mauss S, Baumgarten A, Rockstroh J
J CLIN GASTROENTEROL. 2020;54(2):192-199.

High rates of cirrhosis and severe clinical events in patients with HBV/HDV co-infection:longitudinal analysis of a German cohort:longitudinal analysis of a German cohort
Bockmann J, Grube M, Hamed V, von Felden J, Landahl J, Wehmeyer M, Giersch K, Hall M, Murray J, Dandri M, Lüth S, Lohse A, Lütgehetmann M, Schulze Zur Wiesch J
BMC GASTROENTEROL. 2020;20(1):24.

High effectiveness of multimodal infection control interventions in preventing SARS−CoV−2 infections in healthcare professionals: a prospective longitudinal seroconversion study
Brehm T, Schwinge D, Lampalzer S, Schlicker V, Küchen J, Thompson M, Ullrich F, Huber S, Schmiedel S, Addo M, Lütgehetmann M, Knobloch J, Schulze zur Wiesch J, Lohse A
medRxiv BMJ. 2020.

Characterization of the immune cell landscape of patients with NAFLD
Diedrich T, Kummer S, Galante A, Drolz A, Schlicker V, Lohse A, Kluwe J, Eberhard J, Schulze Zur Wiesch J
PLOS ONE. 2020;15(3):e0230307.

Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection
Dietz J, Kalinina O, Vermehren J, Peiffer K, Matschenz K, Buggisch P, Niederau C, Schattenberg J, Müllhaupt B, Yerly S, Ringelhan M, Schmid R, Antoni C, Müller T, Schulze Zur Wiesch J, Piecha F, Moradpour D, Deterding K, Wedemeyer H, Moreno C, Berg T, Berg C, Zeuzem S, Welsch C, Sarrazin C
J VIRAL HEPATITIS. 2020;27(10):974-986.

Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance-associated substitutions
Dietz J, Vermehren J, Matschenz K, Buggisch P, Klinker H, Schulze Zur Wiesch J, Hinrichsen H, Peiffer K, Graf C, Discher T, Trauth J, Schattenberg J, Piecha F, Mauss S, Niederau C, Müller T, Neumann-Haefelin C, Berg C, Zeuzem S, Sarrazin C
LIVER INT. 2020;40(11):2660-2671.

Vulnerability to reservoir reseeding due to high immune activation after allogeneic hematopoietic stem cell transplantation in individuals with HIV-1
Eberhard J, Angin M, Passaes C, Salgado M, Monceaux V, Knops E, Kobbe G, Jensen B, Christopeit M, Kröger N, Vandekerckhove L, Badiola J, Bandera A, Raj K, van Lunzen J, Hütter G, Kuball J, Martinez-Laperche C, Balsalobre P, Kwon M, Díez-Martín J, Nijhuis M, Wensing A, Martinez-Picado J, Schulze Zur Wiesch J, Sáez-Cirión A
SCI TRANSL MED. 2020;12(542):.

Detection of EXP1-Specific CD4+ T Cell Responses Directed Against a Broad Range of Epitopes Including Two Promiscuous MHC Class II Binders During Acute Plasmodium falciparum Malaria
Heide J, Wildner N, Ackermann C, Wittner M, Marget M, Sette A, Sidney J, Jacobs T, Schulze Zur Wiesch J
FRONT IMMUNOL. 2020;10:3037.

Analysis of Co-inhibitory Receptor Expression in COVID-19 Infection Compared to Acute Plasmodium falciparum Malaria: LAG-3 and TIM-3 Correlate With T Cell Activation and Course of Disease
Herrmann M, Schulte S, Wildner N, Wittner M, Brehm T, Ramharter M, Woost R, Lohse A, Jacobs T, Schulze zur Wiesch J
FRONT IMMUNOL. 2020;11:1870.

Significance of Anti-Nuclear Antibodies and Cryoglobulins in Patients with Acute and Chronic HEV Infection
Horvatits T, Schulze Zur Wiesch J, Polywka S, Buescher G, Lütgehetmann M, Hussey E, Horvatits K, Peine S, Haag F, Addo M, Lohse A, Weiler-Normann C, Pischke S
PATHOGENS. 2020;9(9):.

No link between male infertility and HEV genotype 3 infection
Horvatits T, Varwig-Janssen D, Schulze Zur Wiesch J, Lübke R, Reucher S, Frerk S, Addo M, Schneider S, Lohse A, Luetgehetmann M, Pischke S
GUT. 2020;69(6):1150-1151.

Reinfection with the hepatitis C virus in men who have sex with men after successful treatment with direct-acting antivirals in Germany: Current incidence rates compared with rates during the interferon era
Ingiliz P, Wehmeyer M, Boesecke C, Schulze Zur Wiesch J, Schewe K, Lutz T, Baumgarten A, Simon K, Hueppe D, Rockstroh J, Mauss S, Christensen S
CLIN INFECT DIS. 2020;71(5):1248-1254.

Therapeutic Targeting of Myeloperoxidase Attenuates NASH in Mice
Koop A, Thiele N, Steins D, Michaëlsson E, Wehmeyer M, Scheja L, Steglich B, Huber S, Schulze zur Wiesch J, Lohse A, Heeren J, Kluwe J
HEPATOL COMMUN. 2020;4(10):1441-1458.

Blood and Lymph Node Dissemination of Clonal Genome-Intact Human Immunodeficiency Virus 1 DNA Sequences During Suppressive Antiretroviral Therapy
Kuo H, Banga R, Lee G, Gao C, Cavassini M, Corpataux J, Blackmer J, Zur Wiesch S, Yu X, Pantaleo G, Perreau M, Lichterfeld M
J INFECT DIS. 2020;222(4):655-660.

Decreased Frequency of Intestinal CD39+ γδ+ T Cells With Tissue-Resident Memory Phenotype in Inflammatory Bowel Disease
Libera J, Wittner M, Kantowski M, Woost R, Eberhard J, de Heer J, Reher D, Huber S, Haag F, Schulze Zur Wiesch J
FRONT IMMUNOL. 2020;11:567472.

Sustained response after remdesivir and convalescent plasma therapy in a B-cell depleted patient with protracted COVID-19
Malsy J, Veletzky L, Heide J, Hennigs A, Gil-Ibanez I, Stein A, Lütgehetmann M, Rosien U, Jasper D, Peine S, Hiller J, Haag F, Schmiedel S, Huber S, Jordan S, Addo M, Schulze Zur Wiesch J
CLIN INFECT DIS. 2020;73(11):e4020–e4024.

Clinical evaluation of five different automated SARS-CoV-2 serology assays in a cohort of hospitalized COVID-19 patients
Pflüger L, Bannasch J, Brehm T, Pfefferle S, Hoffmann A, Nörz D, van der Meirschen M, Kluge S, Haddad M, Pischke S, Hiller J, Addo M, Lohse A, Wiesch J, Peine S, Aepfelbacher M, Lütgehetmann M
J CLIN VIROL. 2020;130:104549.

Treatment and re-treatment results of HCV patients in the DAA era
Piecha F, Gänßler J, Ozga A, Wehmeyer M, Dietz J, Kluwe J, Laschtowitz A, von Felden J, Sterneck M, Jordan S, Pischke S, Lohse A, Schulze Zur Wiesch J
PLOS ONE. 2020;15(5):e0232773.

Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion: AWMF-Register-Nr.: 021/012
Sarrazin C, Zimmermann T, Berg T, Hinrichsen H, Mauss S, Wedemeyer H, Zeuzem S
Z GASTROENTEROL. 2020;58(11):1110-1131.

Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R)
Vermehren J, Serfert Y, Cornberg M, Stoehr A, Klinker H, Simon K, Teuber G, Deterding K, Schulze Zur Wiesch J, Jung M, Manns M, Zeuzem S, Wedemeyer H, Sarrazin C
Z GASTROENTEROL. 2020;58(9):841-846.

Frequent neurocognitive deficits after recovery from mild COVID-19
Woo M, Malsy J, Pöttgen J, Seddiq Zai S, Ufer F, Hadjilaou A, Schmiedel S, Addo M, Gerloff C, Heesen C, Schulze zur Wiesch J, Friese M
BRAIN COMMUN. 2020;2(2):fcaa205.

Interleukin-9 protects from early podocyte injury and progressive glomerulosclerosis in Adriamycin-induced nephropathy
Xiong T, Attar M, Gnirck A, Wunderlich M, Becker M, Rickassel C, Puelles V, Meyer-Schwesinger C, Wiech T, Nies J, Divivier M, Fuchs T, Schulze Zur Wiesch J, Taipaleenmäki H, Hoxha E, Wirtz S, Huber T, Panzer U, Turner J
KIDNEY INT. 2020;98(3):615-629.

HCV-specific CD4+ T cells of patients with acute and chronic HCV infection display high expression of TIGIT and other co-inhibitory molecules
Ackermann C, Smits M, Woost R, Eberhard J, Peine S, Kummer S, Marget M, Kuntzen T, Kwok W, Lohse A, Jacobs T, Boettler T, Schulze Zur Wiesch J
SCI REP-UK. 2019;9(1):10624.

Comparative Analysis of the Antiviral Effects Mediated by Type I and III Interferons in Hepatitis B Virus-Infected Hepatocytes
Bockmann J, Stadler D, Xia Y, Ko C, Wettengel J, Schulze Zur Wiesch J, Dandri M, Protzer U
J INFECT DIS. 2019;220(4):567-577.

Safety and efficacy of elvitegravir, dolutegravir, and raltegravir in a real-world cohort of treatment-naïve and -experienced patients
Brehm T, Franz M, Hüfner A, Hertling S, Schmiedel S, Degen O, Kreuels B, Schulze Zur Wiesch J
MEDICINE. 2019;98(32):e16721.

Comprehensive Review of Human Plasmodium falciparum-Specific CD8+ T Cell Epitopes
Heide J, Vaughan K, Sette A, Jacobs T, Schulze Zur Wiesch J
FRONT IMMUNOL. 2019;10:397.

The Clinical Perspective on Hepatitis E
Horvatits T, Schulze Zur Wiesch J, Lütgehetmann M, Lohse A, Pischke S
VIRUSES-BASEL. 2019;11(7):.

Mutations in Hepatitis D Virus Allow It to Escape Detection by CD8+ T Cells and Evolve at the Population Level
Karimzadeh H, Kiraithe M, Oberhardt V, Salimi Alizei E, Bockmann J, Schulze Zur Wiesch J, Budeus B, Hoffmann D, Wedemeyer H, Cornberg M, Krawczyk A, Rashidi-Alavijeh J, Rodríguez-Frías F, Casillas R, Buti M, Smedile A, Alavian S, Heinold A, Emmerich F, Panning M, Gostick E, Price D, Timm J, Hofmann M, Raziorrouh B, Thimme R, Protzer U, Roggendorf M, Neumann-Haefelin C
GASTROENTEROLOGY. 2019;156(6):1820-1833.

Management der saisonalen Influenza 2017/2018: Erfahrungen an einem deutschen Universitätsklinikum
Kraef C, van der Meirschen M, Wichmann D, Kutza M, Restemeyer C, Addo M, Lohse A, Schmiedel S, Kluge S, Schulze Zur Wiesch J
BUNDESGESUNDHEITSBLA. 2019;62(7):870-880.

Detection of a Broad Range of Low-Level Major Histocompatibility Complex Class II-Restricted, Hepatitis Delta Virus (HDV)-Specific T-Cell Responses Regardless of Clinical Status
Landahl J, Bockmann J, Scheurich C, Ackermann C, Matzat V, Heide J, Nuurei T, D'Antonio G, von Felden J, Sette A, Peine S, Lohse A, Lütgehetmann M, Marget M, Sidney J, Schulze Zur Wiesch J
J INFECT DIS. 2019;219(4):568-577.

Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study
Lemoine M, Assoumou L, De Wit S, Girard P, Valantin M, Katlama C, Necsoi C, Campa P, Huefner A, Schulze Zur Wiesch J, Rougier H, Bastard J, Stocker H, Mauss S, Serfaty L, Ratziu V, Menu Y, Schlue J, Behrens G, Bedossa P, Capeau J, Ingiliz P, Costagliola D
JAIDS-J ACQ IMM DEF. 2019;80(4):e86-e94.

Transjugular Intrahepatic Portosystemic Shunt: A Possible Risk Factor for Direct-Acting Antiviral Treatment Failure in Patients With Hepatitis C?
Piecha F, Gänßler J, Jordan S, Ergen C, Ittrich H, Kluwe J, Pischke S, Lohse A, Schulze Zur Wiesch J
HEPATOL COMMUN. 2019;3(5):614-619.

Atypical memory B-cells are associated with Plasmodium falciparum anemia through anti-phosphatidylserine antibodies
Rivera-Correa J, Mackroth M, Jacobs T, Schulze Zur Wiesch J, Rolling T, Rodriguez A
ELIFE. 2019;8:.

Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, Pneumocystis jirovecii-pneumonia): a prospective, randomized, open-label multicenter study (IDEAL-study)
Schäfer G, Hoffmann C, Arasteh K, Schürmann D, Stephan C, Jensen B, Stoll M, Bogner J, Faetkenheuer G, Rockstroh J, Klinker H, Härter G, Stöhr A, Degen O, Bibiza-Freiwald E, Hüfner A, Jordan S, Schulze Zur Wiesch J, Addo M, Lohse A, van Lunzen J, Schmiedel S
AIDS RES THER. 2019;16(1):34.

Comparison of the integrin α4β7 expression pattern of memory T cell subsets in HIV infection and ulcerative colitis
Wittner M, Schlicker V, Libera J, Bockmann J, Horvatits T, Seiz O, Kummer S, Manthey C, Hüfner A, Kantowski M, Rösch T, Degen O, Huber S, Eberhard J, Schulze Zur Wiesch J
PLOS ONE. 2019;14(7):e0220008.

Mucosal-associated invariant T-cell frequency and function in blood and liver of HCV mono- and HCV/HIV co-infected patients with advanced fibrosis
Beudeker B, van Oord G, Arends J, Schulze Zur Wiesch J, van der Heide M, de Knegt R, Verbon A, Boonstra A, Claassen M
LIVER INT. 2018;38(3):458-468.

Epidemiology, clinical and laboratory features of 24 consecutive cases of leptospirosis at a German infectious disease center.
Brehm T, Schulze zur Wiesch J, Lütgehetmann M, Tappe D, Eisermann P, Lohse A, Addo M, Schmiedel S
INFECTION. 2018;46(6):847-853.

Levels of Cytokines in Serum Associate With Development of Hepatocellular Carcinoma in Patients With HCV Infection Treated With Direct-Acting Antivirals
Debes J, van Tilborg M, Groothuismink Z, Hansen B, Schulze Zur Wiesch J, von Felden J, de Knegt R, Boonstra A
GASTROENTEROLOGY. 2018;154(3):515-517.

Kombination von NAFLD Fibrosis Score und transienter Elastografie zur Identifikation mittelgradiger Fibrosestadien (II/III) bei nicht-alkoholischer Fettlebererkrankung
Drolz A, Wehmeyer M, Diedrich T, Piecha F, Schulze Zur Wiesch J, Kluwe J
Z GASTROENTEROL. 2018;56(1):43-50.

Lack of evidence for human serum albumin as major source of HEV infections
Horvatits T, Westhölter D, Peine S, Schulze Zur Wiesch J, Lohse A, Lütgehetmann M, Pischke S
TRANSFUSION MED. 2018;28(6):470-471.

Amino Acid Substitutions within HLA-B*27-Restricted T Cell Epitopes Prevent Recognition by Hepatitis Delta Virus-Specific CD8+ T Cells
Karimzadeh H, Kiraithe M, Kosinska A, Glaser M, Fiedler M, Oberhardt V, Salimi Alizei E, Hofmann M, Mok J, Nguyen M, van Esch W, Budeus B, Grabowski J, Homs M, Olivero A, Keyvani H, Rodríguez-Frías F, Tabernero D, Buti M, Heinold A, Alavian S, Bauer T, Schulze Zur Wiesch J, Raziorrouh B, Hoffmann D, Smedile A, Rizzetto M, Wedemeyer H, Timm J, Antes I, Neumann-Haefelin C, Protzer U, Roggendorf M
J VIROL. 2018;92(13):e01891-17.

Interactions Between KIR3DS1 and HLA-F Activate Natural Killer Cells to Control HCV Replication in Cell Culture
Lunemann S, Schöbel A, Kah J, Fittje P, Hölzemer A, Langeneckert A, Hess L, Poch T, Martrus G, Garcia-Beltran W, Körner C, Ziegler A, Richert L, Oldhafer K, Schulze Zur Wiesch J, Schramm C, Dandri M, Herker E, Altfeld M
GASTROENTEROLOGY. 2018;155(5):1366-1371.

HVEM and CD160: Regulators of Immunopathology During Malaria Blood-Stage
Muscate F, Stetter N, Schramm C, Schulze Zur Wiesch J, Bosurgi L, Jacobs T
FRONT IMMUNOL. 2018;9:2611.

Successful treatment of chronic hepatitis C with ground ledipasvir/sofosbuvir in a patient with Crohn's disease and short bowel syndrome
von Felden J, Scheurich C, Yamamura J, Brainard D, Mogalian E, Lohse A, Schulze Zur Wiesch J
J VIRAL HEPATITIS. 2018;25(2):214-215.

High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection
von Felden J, Vermehren J, Ingiliz P, Mauss S, Lutz T, Simon K, Busch H, Baumgarten A, Schewe K, Hueppe D, Boesecke C, Rockstroh J, Daeumer M, Luebke N, Timm J, Schulze Zur Wiesch J, Sarrazin C, Christensen S
ALIMENT PHARM THER. 2018;47(9):1288-1295.

Editorial: genotype 3 HCV-who still needs ribavirin in a pan-genotypic era? Authors' reply.
von Felden J, Vermehren J, Schulze Zur Wiesch J, Sarrazin C, Christensen S
ALIMENT PHARM THER. 2018;47(11):1550-1551.

Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03)
Wehmeyer M, Ingiliz P, Christensen S, Hueppe D, Lutz T, Simon K, Schewe K, Boesecke C, Baumgarten A, Busch H, Rockstroh J, Schmutz G, Kimhofer T, Berger F, Mauss S, Schulze Zur Wiesch J
J MED VIROL. 2018;90(2):304-312.

HEV-positive blood donations represent a relevant infection risk for immunosuppressed recipients
Westhölter D, Hiller J, Denzer U, Polywka S, Ayuk F, Rybczynski M, Horvatits T, Gundlach S, Blöcker J, Schulze Zur Wiesch J, Fischer N, Addo M, Peine S, Göke B, Lohse A, Lütgehetmann M, Pischke S
J HEPATOL. 2018;69(1):36-42.

CD32 Expression of Different Memory T Cell Subpopulations in the Blood and Lymph Nodal Tissue of HIV Patients and Healthy Controls Correlates With Immune Activation
Wittner M, Dunay G, Kummer S, Bockhorn M, Hüfner A, Schmiedel S, Degen O, van Lunzen J, Eberhard J, Schulze Zur Wiesch J
JAIDS-J ACQ IMM DEF. 2018;77(4):345-349.

Stable Frequencies of HLA-C*03:04/Peptide-Binding KIR2DL2/3+ Natural Killer Cells Following Vaccination
Ziegler M, Grañana F, Garcia-Beltran W, Schulze Zur Wiesch J, Hoffmann C, Rechtien A, Lunemann S, Altfeld M
FRONT IMMUNOL. 2018;9:2361.

Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study
Berg T, Simon K, Mauss S, Schott E, Heyne R, Klass D, Eisenbach C, Welzel T, Zachoval R, Felten G, Schulze-Zur-Wiesch J, Cornberg M, Op den Brouw M, Jump B, Reiser H, Gallo L, Warger T, Petersen J
J HEPATOL. 2017;67(5):918-924.

Liver Cirrhosis as a Risk Factor for Direct-Acting Antiviral Therapy Failure in Real-Life Hepatitis C Virus/Human Immunodeficiency Virus Coinfection
Boesecke C, Ingiliz P, Berger F, Lutz T, Schewe K, Schulze Zur Wiesch J, Baumgarten A, Christensen S, Rockstroh J, Mauss S
OPEN FORUM INFECT DI. 2017;4(3):ofx158.

Autoantibodies against "rods and rings"-related IMPDH2 in hepatitis C genotype 1 and DAA therapy in a "real life" cohort
Dammermann W, Polywka S, Dettmann I, Mindorf S, Komorowski L, Wehmeyer M, Schulze Zur Wiesch J, Stöcker W, Lüth S
MED MICROBIOL IMMUN. 2017;206(5):379-382.

Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV) an open-label, single-arm, phase 2 study
Deterding K, Spinner C, Schott E, Welzel T, Gerken G, Klinker H, Spengler U, Wiegand J, Zur Wiesch J, Pathil A, Cornberg M, Umgelter A, Zöllner C, Zeuzem S, Papkalla A, Weber K, Hardtke S, von der Leyen H, Koch A, von Witzendorff D, Manns M, Wedemeyer H
LANCET INFECT DIS. 2017;17(2):215-222.

Increased frequency of CD39+ CD56 bright Natural Killer cells in HIV-1 infection correlates with immune activation and disease progression
Dierks P, Wroblewski R, Eberhard J, Martrus G, Degen O, Hertling S, Schmiedel S, Lunemann S, Hüfner A, Lohse A, Altfeld M, van Lunzen J, Schulze Zur Wiesch J
JAIDS-J ACQ IMM DEF. 2017;74(4):467-472.

Assessment of the HIV-1 reservoir in CD4+ regulatory T cells by a Droplet Digital PCR based approach
Dunay G, Solomatina A, Kummer S, Hüfner A, Bialek J, Eberhard J, Tolosa E, Hauber J, Wiesch J
VIRUS RES. 2017;240:107-111.

Down-regulation of CD73 on B cells of patients with viremic HIV correlates with B cell activation and disease progression
Kim E, Ackermann C, Tóth I, Dierks P, Eberhard J, Wroblewski R, Scherg F, Geyer M, Schmidt R, Beisel C, Bockhorn M, Haag F, Lunzen J, Schulze Zur Wiesch J
J LEUKOCYTE BIOL. 2017;101(5):1263-1271.

Circulating CXCR5(+)CXCR3(+)PD-1(lo) Tfh-like cells in HIV-1 controllers with neutralizing antibody breadth
Martin-Gayo E, Cronin J, Hickman T, Ouyang Z, Lindqvist M, Kolb K, Schulze Zur Wiesch J, Cubas R, Porichis F, Shalek A, Lunzen J, Haddad E, Walker B, Kaufmann D, Lichterfeld M, Yu X
JCI INSIGHT. 2017;2(2):e89574.

High clinical manifestation rate in an imported outbreak of hepatitis E genotype 1 infection in a German group of travellers returning from India
Pischke S, Schulze zur Wiesch J, Lütgehetmann M, Kreuels B, Lüth S, Kapaun P, Benten D, Schmiedel S, Sterneck M, Lohse A, Polywka S
ANN HEPATOL. 2017;16(1):57-62.

Infections complicating severe alcoholic Hepatitis: Enterococcus species represent the most frequently identified pathogen
Beisel C, Blessin U, Schulze Zur Wiesch J, Wehmeyer M, Lohse A, Benten D, Kluwe J
SCAND J GASTROENTERO. 2016;51(7):807-13.

Increased CD56(bright) NK cells in HIV-HCV co-infection and HCV mono-infection are associated with distinctive alterations of their phenotype
Bhardwaj S, Ahmad F, Wedemeyer H, Cornberg M, Schulze Zur Wiesch J, Lunzen J, Sarin S, Schmidt R, Meyer-Olson D
J VIROL. 2016;13:67.

Parallel assessment of Th17 cell frequencies by surface marker co-expression versus ex vivo IL-17 production in HIV-1 infection
Dunay G, Tóth I, Eberhard J, Degen O, Tolosa E, Lunzen J, Hauber J, Zur Wiesch J
CYTOM PART B-CLIN CY. 2016;90(6):486-492.

Partial recovery of senescence and differentiation disturbances in CD8(+) T cell effector-memory cells in HIV-1 nfection after initiation of anti-retroviral treatment.
Eberhard J, Ahmad F, Hong H, Bhatnagar N, Keudel P, Schulze zur Wiesch J, Schmidt R, Meyer-Olson D
CLIN EXP IMMUNOL. 2016;186(2):227-238.

Reduced CD161(+) MAIT cell frequencies in HCV and HIV/HCV co-infection: Is the liver the heart of the matter?
Eberhard J, Kummer S, Hartjen P, Hüfner A, Diedrich T, Degen O, Lohse A, Lunzen J, Schulze Zur Wiesch J
J HEPATOL. 2016;65(6):1261-1263.

Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV-Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01).
Ingiliz P, Christensen S, Kimhofer T, Hueppe D, Lutz T, Schewe K, Busch H, Schmutz G, Wehmeyer M, Boesecke C, Simon K, Berger F, Rockstroh J, Schulze zur Wiesch J, Baumgarten A, Mauss S
CLIN INFECT DIS. 2016;63(10):1320-1324.

New findings in HCV genotype distribution in selected West European, Russian and Israeli regions
Kartashev V, Döring M, Nieto L, Coletta E, Kaiser R, Sierra S
J CLIN VIROL. 2016;81:82-9.

Acute Malaria Induces PD1+CTLA4+ Effector T Cells with Cell-Extrinsic Suppressor Function
Mackroth M, Abel A, Steeg C, Schulze Zur Wiesch J, Jacobs T
PLOS PATHOG. 2016;12(11):e1005909.

Cytokine and Chemokine Signature in Elite versus Viremic Controllers infected with HIV
Platten M, Jung N, Trapp S, Floßdorf P, Meyer-Olson D, Schulze Zur Wiesch J, Stephan C, Mauss S, Weiß V, von Bergwelt-Balidon M, Rockstroh J, Fätkenheuer G, Lehmann C
AIDS RES HUM RETROV. 2016;32(6):579-87.

High proportion of HIV late presenters at an academic tertiary care center in northern Germany confirms the results of several cohorts in Germany: time to put better HIV screening efforts on the national agenda?
Schäfer G, Kreuels B, Schmiedel S, Hertling S, Hüfner A, Degen O, Lunzen J, Schulze Zur Wiesch J
INFECTION. 2016;44(3):347-52.

Breadth of the HCV-specific CD4+ T-cell response in spontaneous resolvers is independent of the IL-28 haplotype
Scheurich C, Schulze Zur Wiesch J, Kim A, Lewis-Ximenez L, Meyer T, Polywka S, Chung R, Lauer G
J VIRAL HEPATITIS. 2016;23(10):831-2.

Medizinische Versorgung von Flüchtlingen – Eine Fallserie des Universitätsklinikums Hamburg-Eppendorf
Sothmann P, Schmedt auf der Günne N, Roggelin L, Kreuels B, Rothe C, Addo M, Lohse A, Schulze zur Wiesch J, Schmiedel S
FLUGMEDIZIN TROPENME. 2016;23(1):45-49.

Nonalcoholic fatty liver disease is associated with excessive calorie intake rather than a distinctive dietary pattern
Wehmeyer M, Zyriax B, Jagemann B, Roth E, Windler E, Schulze Zur Wiesch J, Lohse A, Kluwe J
MEDICINE. 2016;95(23):e3887.

Development of a novel IGRA assay to test T cell responsiveness to HBV antigens in whole blood of chronic Hepatitis B patients
Dammermann W, Bentzien F, Stiel E, Kühne C, Ullrich S, Schulze Zur Wiesch J, Lüth S
J TRANSL MED. 2015;13(2015):Art. 157.

CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X
Karimova M, Beschorner N, Dammermann W, Chemnitz J, Indenbirken D, Bockmann J, Grundhoff A, Lüth S, Buchholz F, Schulze zur Wiesch J, Hauber J
SCI REP-UK. 2015;5:13734.

Increased Frequency of CD49b/LAG-3(+) Type 1 Regulatory T Cells in HIV-Infected Individuals
Koch K, Koch N, Sandaradura de Silva U, Jung N, Schulze Zur Wiesch J, Fätkenheuer G, Hartmann P, Romerio F, Lehmann C
AIDS RES HUM RETROV. 2015;31(12):1238-46.

Low SAMHD1 expression following T-cell activation and proliferation renders CD4+ T cells susceptible to HIV-1
Ruffin N, Brezar V, Ayinde D, Lefebvre C, Schulze Zur Wiesch J, Lunzen J, Bockhorn M, Schwartz O, Hocini H, Lelievre J, Banchereau J, Levy Y, Seddiki N
AIDS. 2015;29(5):519-30.

The elephant and the blind men: making sense of the seemingly multifaceted role of Blimp-1 in HIV-1 infection
Schulze Zur Wiesch J, Beisel C
AIDS. 2015;29(1):134-6.

Efficacy and safety of sofosbuvir-based triple therapy in hepatitis C genotype 4 infection.
Wehmeyer M, Jordan S, Lüth S, Hartl J, Stoehr A, Eißing C, Lohse A, Petersen J, Buggisch P, Schulze zur Wiesch J
DIGEST LIVER DIS. 2015;47(9):811-814.

German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients
Beisel C, Heuer M, Otto B, Jochum J, Schmiedel S, Hertling S, Degen O, Lüth S, Lunzen J, Schulze Zur Wiesch J
AIDS RES THER. 2014;11:16.

Reduced expression of Blimp-1 in memory B cells in patients with HIV-1 infection suggests distinct roles of this molecule for B and T cell regulation
Beisel C, Toth I, Lunzen J, Schulze Zur Wiesch J
AIDS. 2014;28(16):2489-2491.

CD161+ MAIT cells are severely reduced in peripheral blood and lymph nodes of HIV-infected individuals independently of disease progression
Eberhard J, Hartjen P, Kummer S, Schmidt R, Bockhorn M, Lehmann C, Balagopal A, Hauber J, Lunzen J, Schulze zur Wiesch J
PLOS ONE. 2014;9(11):e111323.

Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection
Roeder C, Jordan S, Schulze Zur Wiesch J, Pfeiffer-Vornkahl H, Hueppe D, Mauss S, Zehnter E, Stoll S, Alshuth U, Lohse A, Lüth S
WORLD J GASTROENTERO. 2014;20(31):10984-10993.

Leberzirrhose - Was bringen die neuen Substanzen?
Schulze zur Wiesch J, Lüth S
Hepatitis and more. 2014;1:25-28.

Safety and efficacy of protease inhibitor based combination therapy in a single-center "real-life" cohort of 110 patients with chronic hepatitis C genotype 1 infection
Wehmeyer M, Eißing F, Jordan S, Röder C, Hennigs A, Degen O, Hüfner A, Hertling S, Schmiedel S, Sterneck M, Lunzen J, Lohse A, Schulze Zur Wiesch J, Lüth S
BMC GASTROENTEROL. 2014;14:87.

Increased expression of complement regulators CD55 and CD59 on peripheral blood cells in patients with EAHEC O104:H4 infection
Dammermann W, Schipper P, Ullrich S, Zimmermann-Fraedrich K, Schulze Zur Wiesch J, Fründt T, Tiegs G, Lohse A, Lüth S
PLOS ONE. 2013;8(9):e74880.

The NTPase/helicase domain of hepatitis C virus nonstructural protein 3 inhibits protein kinase C independently of its NTPase activity
Hartjen P, Höchst B, Heim D, von der Kammer H, Lucke J, Reinholz M, Baier A, Smeets R, Wege H, Borowski P, Schulze Zur Wiesch J
CELL MOL BIOL LETT. 2013;18(3):447-58.

Vγ2Vδ2 T cells are skewed toward a terminal differentiation phenotype in untreated HIV infection
Hartjen P, Meyer-Olson D, Lehmann C, Stellbrink H, van Lunzen J, Schulze zur Wiesch J
J INFECT DIS. 2013;208(1):180-2.

Functional characterization of HLA-G⁺ regulatory T cells in HIV-1 infection
Li C, Toth I, Schulze Zur Wiesch J, Pereyra F, Rychert J, Rosenberg E, van Lunzen J, Lichterfeld M, Yu X
PLOS PATHOG. 2013;9(1):e1003140.

Improved treatment for primary HIV infection by interferon-alfa therapy? Does HCV treatment in HIV/HCV coinfected patients help us to test this hypothesis?
Schulze Zur Wiesch J, van Lunzen J
J INFECT DIS. 2013;208(2):362-363.

Decreased frequency of CD73+CD8+ T cells of HIV-infected patients correlates with immune activation and T cell exhaustion
Tóth I, Le A, Hartjen P, Thomssen A, Matzat V, Lehmann C, Scheurich C, Beisel C, Busch C, Degen O, Lohse A, Eiermann T, Fätkenheuer G, Meyer-Olson D, Bockhorn M, Hauber J, Lunzen J, Schulze Zur Wiesch J
J LEUKOCYTE BIOL. 2013;94(4):551-61.

Assessment of the range of the HIV-1 infectivity enhancing effect of individual human semen specimen and the range of inhibition by EGCG.
Hartjen P, Frerk S, Hauber I, Matzat V, Thomssen A, Holstermann B, Hohenberg H, Schulze W, Schulze Zur Wiesch J, van Lunzen J
AIDS RES THER. 2012;9(1):2.

Expansion of HIV-specific T follicular helper cells in chronic HIV infection.
Lindqvist M, van Lunzen J, Soghoian D, Kuhl B, Ranasinghe S, Kranias G, Flanders M, Cutler S, Yudanin N, Muller M, Davis I, Farber D, Hartjen P, Haag F, Alter G, Schulze Zur Wiesch J, Streeck H
J CLIN INVEST. 2012;122(9):3271-3280.

Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence.
Schulze Zur Wiesch J, Ciuffreda D, Lewis-Ximenez L, Kasprowicz V, Nolan B, Streeck H, Aneja J, Reyor L, Allen T, Lohse A, McGovern B, Chung R, Kwok W, Kim A, Lauer G
J EXP MED. 2012;209(1):61-75.

The transhepatic endotoxin gradient is present despite liver cirrhosis and is attenuated after transjugular portosystemic shunt (TIPS).
Benten D, Schulze Zur Wiesch J, Sydow K, Koops A, Buggisch P, Böger R, Gaydos C, Won H, Franco V, Lohse A, Ray S, Balagopal A
BMC GASTROENTEROL. 2011;11:107.

Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes.
Kim A, Kuntzen T, Timm J, Nolan B, Baca M, Reyor L, Berical A, Feller A, Johnson K, Schulze Zur Wiesch J, Robbins G, Chung R, Walker B, Carrington M, Allen T, Lauer G
GASTROENTEROLOGY. 2011;140(2):681-686.

Real-Life comparison of pegylated-interferon 2a versus 2b combination therapy of chronic hepatitis C virus.
Schulze Zur Wiesch J, Pudelski N, Hoepner L, Supplieth M, Buggisch P, Lohse A, Lüth S
HEPATOLOGY. 2011;53(4):1405-1407.

Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FoxP3+ T regulatory cells correlates with progressive disease.
Schulze Zur Wiesch J, Thomssen A, Hartjen P, Toth I, Lehmann C, Meyer-Olson D, Colberg K, Frerk S, Babikir D, Schmiedel S, Degen O, Mauss S, Rockstroh J, Staszewski S, Khaykin P, Strasak A, Lohse A, Fätkenheuer G, Hauber J, van Lunzen J
J VIROL. 2011;85(3):1287-1297.

Hide and seek... Can we eradicate HIV by treatment intensification?
Schulze Zur Wiesch J, van Lunzen J
J INFECT DIS. 2011;203(7):894-897.

Antibody dynamics and spontaneous viral clearance in patients with acute hepatitis C infection in Rio de Janeiro, Brazil.
Strasak A, Kim A, Lauer G, Sousa d, Paulo S, Ginuino C, Fernandes C, Velloso C, Almeida d, Adilson J, Schulze Zur Wiesch J, Jaqueline M, Yoshida C, Julian S, Paranhos-Baccalá G, Lang S, Brant L, Ulmer H, Strohmaier S, Kaltenbach L, Lampe E, Lewis-Ximenez L
BMC INFECT DIS. 2011;11:15.

Hepatitis C virus (HCV) sequence variation induces an HCV-specific T-cell phenotype analogous to spontaneous resolution.
Kasprowicz V, Kang Y, Lucas M, Schulze Zur Wiesch J, Kuntzen T, Fleming V, Nolan B, Longworth S, Berical A, Bengsch B, Thimme R, Lewis-Ximenez L, Allen T, Kim A, Klenerman P, Lauer G
J VIROL. 2010;84(3):1656-1663.

Prospective follow-up of patients with acute hepatitis C virus infection in Brazil.
Lewis-Ximenez L, Lauer G, Schulze Zur Wiesch J, Sousa d, Fonseca P, Ginuino C, Paranhos-Baccalá G, Ulmer H, Pfeiffer K, Goebel G, Pereira J, Jaqueline M, Yoshida C, Lampe E, Velloso C, Marcelo A, Coelho H, Almeida A, Fernandes C, Kim A, Strasak A
CLIN INFECT DIS. 2010;50(9):1222-1230.

Genomic Tandem Repeat Analysis Proves Laboratory-Acquired Brucellosis in Veterinary (Camel) Diagnostic Laboratory in the United Arab Emirates.
Schulze Zur Wiesch J, Wichmann D, Sobottka I, Rohde H, Schmoock G, Wernery R, Schmiedel S, Burchard G, Melzer F
ZOONOSES PUBLIC HLTH. 2010;57(5):315-317.

Results of the IDEAL trial: "Mirror, mirror on the wall ... which's the fairest peg-interferon of them all?".
Schulze Zur Wiesch J, Lohse A
HEPATOLOGY. 2009;50(6):2034-2037.

Sustained virological response after early antiviral treatment of acute hepatitis C virus and HIV coinfection.
Schulze Zur Wiesch J, Pieper D, Stahmer I, Eiermann T, Buggisch P, Lohse A, Hauber J, van Lunzen J
CLIN INFECT DIS. 2009;49(3):466-472.

High level of PD-1 expression on hepatitis C virus (HCV)-specific CD8+ and CD4+ T cells during acute HCV infection, irrespective of clinical outcome.
Kasprowicz V, Schulze Zur Wiesch J, Kuntzen T, Nolan B, Longworth S, Berical A, Blum J, McMahon C, Reyor L, Elias N, Kwok W, McGovern B, Freeman G, Chung R, Klenerman P, Lewis-Ximenez L, Walker B, Allen T, Kim A, Lauer G
J VIROL. 2008;82(6):3154-3160.

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients.
Kuntzen T, Timm J, Berical A, Lennon N, Berlin A, Young S, Lee B, Heckerman D, Carlson J, Reyor L, Kleyman M, McMahon C, Birch C, Schulze Zur Wiesch J, Ledlie T, Koehrsen M, Kodira C, Roberts A, Lauer G, Rosen H, Bihl F, Cerny A, Spengler U, Liu Z, Kim A, Xing Y, Schneidewind A, Madey M, Fleckenstein J, Park V, Galagan J, Nusbaum C, Walker B, Lake-Bakaar G, Daar E, Jacobson I, Gomperts E, Edlin B, Donfield S, Chung R, Talal A, Marion T, Birren B, Henn M, Allen T
HEPATOLOGY. 2008;48(6):1769-1778.

Primary HIV infection presenting as haemolytic crisis in a patient with previously undiagnosed glucose 6-phosphate dehydrogenase deficiency.
Schulze Zur Wiesch J, Wichmann D, Hennigs A, van Lunzen J, Burchard G, Schmiedel S
AIDS. 2008;22(14):1886-1888.

Viral sequence evolution in acute hepatitis C virus infection
Kuntzen T, Timm J, Berical A, Lewis-Ximenez L, Jones A, Nolan B, Schulze zur Wiesch J, Li B, Schneidewind A, Kim A, Chung R, Lauer G, Allen T
J VIROL. 2007;81(21):11658-68.

Human leukocyte antigen-associated sequence polymorphisms in hepatitis C virus reveal reproducible immune responses and constraints on viral evolution
Timm J, Li B, Daniels M, Bhattacharya T, Reyor L, Allgaier R, Kuntzen T, Fischer W, Nolan B, Duncan J, Schulze zur Wiesch J, Kim A, Frahm N, Brander C, Chung R, Lauer G, Korber B, Allen T
HEPATOLOGY. 2007;46(2):339-49.

Outcomes and treatment of acute hepatitis C virus infection in a United States population
Corey K, Ross A, Wurcel A, Schulze Zur Wiesch J, Kim A, Lauer G, Chung R
CLIN GASTROENTEROL H. 2006;4(10):1278-82.

Impaired hepatitis C virus-specific T cell responses and recurrent hepatitis C virus in HIV coinfection
Kim A, Schulze zur Wiesch J, Kuntzen T, Timm J, Kaufmann D, Duncan J, Jones A, Wurcel A, Davis B, Gandhi R, Robbins G, Allen T, Chung R, Lauer G, Walker B
PLOS MED. 2006;3(12):e492.

Acute hepatitis C virus infection in incarcerated injection drug users
McGovern B, Wurcel A, Kim A, Schulze zur Wiesch J, Bica I, Zaman M, Timm J, Walker B, Lauer G
CLIN INFECT DIS. 2006;42(12):1663-1670.

The magnitude and breadth of hepatitis C virus-specific CD8+ T cells depend on absolute CD4+ T-cell count in individuals coinfected with HIV-1
Kim A, Lauer G, Ouchi K, Addo M, Lucas M, Schulze Zur Wiesch J, Timm J, Boczanowski M, Duncan J, Wurcel A, Casson D, Chung R, Draenert R, Klenerman P, Walker B
BLOOD. 2005;105(3):1170-8.

Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy
Lauer G, Lucas M, Timm J, Ouchi K, Kim A, Day C, Schulze Zur Wiesch J, Paranhos-Baccala G, Sheridan I, Casson D, Reiser M, Gandhi R, Li B, Allen T, Chung R, Klenerman P, Walker B
J VIROL. 2005;79(20):12979-12988.

Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes
Schulze zur Wiesch J, Lauer G, Day C, Kim A, Ouchi K, Duncan J, Wurcel A, Timm J, Jones A, Mothe B, Allen T, McGovern B, Lewis-Ximenez L, Sidney J, Sette A, Chung R, Walker B
J IMMUNOL. 2005;175(6):3603-13.

CD8 epitope escape and reversion in acute HCV infection
Timm J, Lauer G, Kavanagh D, Sheridan I, Kim A, Lucas M, Pillay T, Ouchi K, Reyor L, Schulze zur Wiesch J, Gandhi R, Chung R, Bhardwaj N, Klenerman P, Walker B, Allen T
J EXP MED. 2004;200(12):1593-1604.

The proteins of the Hepatitis C Virus: their features and interactions with intracellular protein phosphorylation
Schulze zur Wiesch J, Schmitz H, Borowski E, Borowski P
ARCH VIROL. 2003;148(7):1247-67.

Inhibition of the helicase activity of HCV NTPase/helicase by 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide-5 '-triphosphate (ribavirin-TP)
Borowski P, Lang M, Niebuhr A, Haag A, Schmitz H, Schulze zur Wiesch J, Choe J, Siwecka M, Kulikowski T
ACTA BIOCHIM POL. 2001;48(3):739-44.

Biochemical properties of a minimal functional domain with ATP-binding activity of the NTPase/helicase of hepatitis C virus
Borowski P, Kuehl R, Mueller O, Hwang L, Schulze Zur Wiesch J, Schmitz H
EUR J BIOCHEM. 1999;266(3):715-23.

Identification and characterization of a histone binding site of the non-structural protein 3 of hepatitis C virus
Borowski P, Kühl R, Laufs R, Schulze zur Wiesch J, Heiland M
J CLIN VIROL. 1999;13(1-2):61-9.

Protein kinase C recognizes the protein kinase A-binding motif of nonstructural protein 3 of hepatitis C virus
Borowski P, Schulze zur Wiesch J, Resch K, Feucht H, Laufs R, Schmitz H
J BIOL CHEM. 1999;274(43):30722-8.

Letzte Aktualisierung aus dem FIS: 24.12.2024 - 03:52 Uhr